Can glargine reduce the number of lung infections in patients with cystic fibrosis-related diabetes?

Diabetes Care. 2005 Sep;28(9):2333. doi: 10.2337/diacare.28.9.2333.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Cystic Fibrosis / complications*
  • Cystic Fibrosis / genetics
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / etiology*
  • Forced Expiratory Volume
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Insulin / analogs & derivatives*
  • Insulin / therapeutic use
  • Insulin Glargine
  • Insulin, Long-Acting
  • Lung / drug effects
  • Lung / physiopathology*
  • Sequence Deletion

Substances

  • CFTR protein, human
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Insulin Glargine